These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20839576)

  • 41. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. U.S Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Berman JD
    Clin Infect Dis; 1999 Jan; 28(1):49-51. PubMed ID: 10391695
    [No Abstract]   [Full Text] [Related]  

  • 43. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 44. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
    Brown M; Noursadeghi M; Boyle J; Davidson RN
    Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
    Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
    J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of visceral leishmaniasis in 2004.
    Murray HW
    Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amphotericin B in resistant kala-azar in Bihar.
    Thakur CP; Sinha GP; Pandey AK; Barat D; Sinha PK
    Natl Med J India; 1993; 6(2):57-60. PubMed ID: 8477209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar.
    Thakur CP; Sinha GP; Sharma V; Pandey AK; Kumar M; Verma BB
    Indian J Med Res; 1993 Jul; 97():170-5. PubMed ID: 8406644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.
    Mueller M; Ritmeijer K; Balasegaram M; Koummuki Y; Santana MR; Davidson R
    Trans R Soc Trop Med Hyg; 2007 Jan; 101(1):19-24. PubMed ID: 16730363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison.
    Thakur CP; Sinha GP; Pandey AK; Barat D; Singh RK
    Bull World Health Organ; 1994; 72(6):931-6. PubMed ID: 7867139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis.
    Sundar S; Goyal AK; Mandal AK; Makharia MK; Singh VP; Murray HW
    J Assoc Physicians India; 1999 Feb; 47(2):186-8. PubMed ID: 10999086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.
    Sundar S; Murray HW
    J Infect Dis; 1996 Mar; 173(3):762-5. PubMed ID: 8627049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis in Children and Adolescents at a Tertiary Care Center in Bihar, India.
    Pandey K; Pal B; Siddiqui NA; Rabi Das VN; Murti K; Lal CS; Verma N; Babu R; Ali V; Kumar R; Das P
    Am J Trop Med Hyg; 2017 Nov; 97(5):1498-1502. PubMed ID: 29016288
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 58. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompromised patients.
    Vigna E; De Vivo A; Gentile M; Morelli R; Lucia E; Mazzone C; Recchia AG; Vianelli N; Morabito F
    Transpl Infect Dis; 2010 Oct; 12(5):428-31. PubMed ID: 20534035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study.
    Mondal D; Alvar J; Hasnain MG; Hossain MS; Ghosh D; Huda MM; Nabi SG; Sundar S; Matlashewski G; Arana B
    Lancet Glob Health; 2014 Jan; 2(1):e51-7. PubMed ID: 25104636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.
    Meheus F; Balasegaram M; Olliaro P; Sundar S; Rijal S; Faiz MA; Boelaert M
    PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20838649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.